Company Profile

Lipocine Inc. Stock Price, News & Catalysts

Ticker:
LPCN
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

1.50 USD (-1.32%)

Close

Last updated: November 19, 2026

18.5M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, LPCN closed down 1.32% at $1.50. No new same-company headline was identified in the current news window.

Company overview

Oral Drug-Delivery Platform

Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.

LPCN 1154

LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future development path uncertain.

Product-Focused Development Model

The company applies its formulation technology to established active pharmaceutical ingredients, seeking differentiated dosing, convenience or pharmacokinetic profiles in endocrine and neuropsychiatric indications.

Broader Neuroendocrine Pipeline

Additional programs apply oral formulation technology to major depressive disorder, essential tremor, epilepsy, obesity-related body composition, liver cirrhosis and prevention of preterm birth.

Future catalysts

  • Partner launches of TLANDO in Canada and TESTYRA in the United Arab Emirates in early 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Lipocine Inc. (LPCN)?

Lipocine Inc. (LPCN) most recently closed at 1.50 USD, a -1.32% move versus the previous session.

What is the market cap of Lipocine Inc. (LPCN)?

Lipocine Inc. currently has a market capitalization of 18.5M USD on BioPharmSignal.

What does Lipocine Inc. do?

Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth. LPCN 1154 LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future...

On which exchange is LPCN stock listed?

Lipocine Inc. (LPCN) is associated with NASDAQ, United States, Biopharma.

What is Oral?

Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.

Which conditions is Lipocine Inc. targeting with Oral?

Lipocine Inc. is associated with obesity based on its company overview and current catalyst commentary.

How does Lipocine Inc. describe recent progress with Oral?

Partner launches of TLANDO in Canada and TESTYRA in the United Arab Emirates in early 2027.

What is Drug-Delivery?

Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.